Xaar PLC
15 March 2005
FOR IMMEDIATE RELEASE 15 March 2005
Xaar plc
JOINT DEVELOPMENT ON NANO TECHNOLOGY WITH
MOLECULAR IMPRINTS
Xaar plc ('Xaar'), the inkjet printing technology group headquartered in
Cambridge, is pleased to announce a Joint Development Agreement with Molecular
Imprints Inc. ('MII') of Austin, TX, USA. MII, a spinout from the University of
Texas, has developed a unique combination of lithography and 3-dimensional
printing to pattern nano-scale devices and structures incorporating Xaar's
inkjet technology.
The MII technique is based on a Step and Flash Imprint Lithography (S-FILTM)
process, and MII holds over 100 patents covering all aspects of the technology
and its implementation. MII has developed a range of equipment using the S-FIL
process in conjunction with Xaar's inkjet printheads and electronics from Xaar
subsidiary, Vivid Print Innovations Inc. This equipment is now being sold to
integrated circuit makers, chip makers and device makers in a wide range of
markets including semi-conductor component devices, photonic and optical
structures, nano fabrication, data storage and advanced packaging.
MII sells its equipment direct to end users or via distributors which include
Carl Zeiss SMT, KLA Tencor Corp. and Hakuto.
Commenting on the agreement, Nigel Berry, head of business development for Xaar,
said; 'I am delighted to announce this tie up with MII, a leading innovator in
the use of imprint lithography to radically restructure future production
processes in the semiconductor and device market. Not only did the team at MII
develop their unique technology, but they went on to raise significant funding
in order to commercialise it, and have now brought an impressive range of
equipment to market. We are pleased they consider Xaar and its technology to be
an ideal partner for them and we look forward to working with them to
incorporate the next generation of our technology into their development
programme.' (www.xaar.co.uk).
Commenting from MII, S.V. Sreenivasan, CT0, said: 'We are pleased to announce
this agreement with Xaar and Vivid. These two companies are the leaders in
fluid dispense technology and will continue to provide the pioneering work
required for our nanolithography applications. We look forward to a long and
productive relationship with them.' (www.molecularimprints.com).
Ends
Contacts
Xaar plc: 01223-423663
Ian Dinwoodie, Chief Executive www.xaar.co.uk
Nigel Berry, Group Finance Director & Deputy Chief Executive
Bankside Consultants:
Steve Liebmann 020-7444-4163 / 07802-888159
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.